Extracurricular laboratory: Synthetic route of 2,4,6-Trichloropyrimidine

With the rapid development of chemical substances, we look forward to future research findings about 3764-01-0.

The major producers of chemicals have been the Europe, Japan and China. Due to the growing call for a cleaner, greener environment, people will have to find innovative ways to maintain their relevance. Here is a compound 3764-01-0, name is 2,4,6-Trichloropyrimidine. This compound has unique chemical properties. The synthetic route is as follows. name: 2,4,6-Trichloropyrimidine

i22 i23 2,4,6-Trichloropyrimidine (Manchester Organics, product number Y17832, 1 1.2 g, 61 mmol, 1.0 eq.), N,N-diisopropylethylamine (23.3 mL, 134.2 mmol, 2.2 eq.) and morpholine (1 1.7 mL, 134.2 mmol, 2.2 eq.) are charged in a flask and dissolved in ethanol (120 mL). The flask is equipped with a refluxed condenser and placed in an oil bath preheated at 100 C. The reaction mixture is stirred at this temperature for 18 hours. After this time, the reaction mixture is cooled down to room temperature and volatiles are removed under reduced pressure. The resulting mixture is dissolved in dichloromethane (100 mL) and washed twice with an aqueous solution of sodium bisulfate (2 x 80 mL). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure using a rotary evaporator. Products i22 and i23 are isolated by flash chromatography on silica gel (cyclohexane / ethyl acetate 3 : 1 to 1 : 1). The product fractions are pooled and evaporated to yield i22 as a colorless powder (13.8 g, 80%) and i23 as a colorless powder (2.2 g, 13% yield). 4,4′-(6-chloropyrimidine-2,4-diyl)dimorpholine (i22): 1H NMR (400 MHz, CDC13): delta 5.85 (s, 1 H), 3.71-3.75 (m, 12 H), 3.52-3.55 (m, 4 H); MS (MALDI): m/z: 285.4 ([M+H]+).4,4′-(2-chloropyrimidine-4,6-diyl)dimorpholine (i23): 1H NMR (400 MHz, CDC13): delta 5.38 (s, 1 H), 3.73-3.76 (m, 8 H), 3.52-3.54 (m, 8 H); MS (MALDI): m/z: 285.2 ([M+H]+).

With the rapid development of chemical substances, we look forward to future research findings about 3764-01-0.

Reference:
Patent; PIQUR THERAPEUTICS AG; THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA; FABBRO, Doriano; HEBEISEN, Paul; HILLMANN-WUELLNER, Petra; STUETZ, Anton; SEYKORA, John, T.; BEAUFILS, Florent; (182 pag.)WO2017/198347; (2017); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia